Scientific Excellence Delivered Through Scientific Advisory Boards
Synexus has pioneered the use of dedicated Scientific Advisory Boards (SABs), to keep pace with innovation and scientific advances in medicine and clinical trials.
Professor Trevor Jones, CBE is the president of the Synexus Scientific Advisory Boards.
The Scientific Advisory boards are each chaired by distinguish Key Opinion Leaders (KOLs) in their field.
Professor Clive Page
Professor Mark Kearney
Professor Peter Grant
Professor Clive Ballard
Please contact us for details.
Our boards have representatives, such as Key Opinion Leaders, from our Synexus countries. Our SABs provide medical insight to our global operation, facilitate the future development of our clinical research services and provide expertise and training for Synexus clinical research staff.
New Scientific Developments.
Advisory boards constantly engage with scientific developments in our key therapeutic areas to ensure we stay ahead of, and plan for, potential changes in clinical practice.
Understanding the drug development pipeline:
Synexus continually review the drug development pipeline to identify potential new clinical areas of drug development that we may be able to support. Mild Cognitive Impairment is one such area we have identified.
Maximising our patient recruitment and retention.
Advisory boards allow details of protocols and their impact on patient recruitment and retention to be discussed.